Carl Hansen, AbCellera CEO (AbCellera)
Lilly's Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants
As the virus behind the Covid-19 pandemic continues to mutate into several variants of concern, the company behind Eli Lilly’s bamlanivimab antibody treatment is looking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.